Surveillance donor-specific antibody and pathologic antibody-mediated rejection testing in heart transplant patients in the contemporary era
Surveillance DSA testing may effectively identify high-risk pAMR+ patients. Earlier DSA testing at 10 to 14 days post-HTx should also be considered in moderate or severe PGD patients.
Authors
- Gerald P. Morris (ORCID: https://orcid.org/0000-0002-1097-4453)
- Victor Pretorius (ORCID: https://orcid.org/0000-0001-6360-4002)
- Nicholas Wettersten (ORCID: https://orcid.org/0000-0002-6122-1152)
- Vincenzo Cusi (ORCID: https://orcid.org/0000-0001-9681-6896)
- Florin Vaida (ORCID: https://orcid.org/0000-0002-2256-4611)
- Ashley Cardenas
- Marcus A. Urey (ORCID: https://orcid.org/0000-0001-8311-5003)
- Grace Lin (ORCID: https://orcid.org/0000-0001-8018-5604)
- Yuko Tada (ORCID: https://orcid.org/0000-0003-1410-9894)
- Jennifer Chak (ORCID: https://orcid.org/0009-0005-5828-1049)
- Paul Kim (ORCID: https://orcid.org/0000-0002-1755-6182)
Institutions
- UC San Diego Health System (US)
- University of California San Diego (US)
- VA San Diego Healthcare System (US)
Publication Details
- Journal
- The Journal of Heart and Lung Transplantation
- Published
- 2025-02-04
- DOI
- https://doi.org/10.1016/j.healun.2025.01.019
- Citations
- 4
- Primary Topic
- Transplantation: Methods and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 8.03
Funders
- Foundation for the National Institutes of Health
- U.S. Department of Veterans Affairs